$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp

2022 Q3 Form 10-Q Financial Statement

#000121390022046902 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $2.011M $32.05K $36.58K
YoY Change 3672.82% -20.07% -4.62%
Cost Of Revenue $83.85K $38.46K $72.81K
YoY Change 28.07% -37.9% 84.98%
Gross Profit $1.927M -$6.413K -$36.23K
YoY Change -15950.66% -70.64% 3487.13%
Gross Profit Margin 95.83% -20.01% -99.04%
Selling, General & Admin $1.889M $1.530M $1.818M
YoY Change 16.37% -28.17% 38.45%
% of Gross Profit 98.03%
Research & Development $1.438M $1.225M $1.205M
YoY Change 42.64% 35.98% 11.46%
% of Gross Profit 74.62%
Depreciation & Amortization $33.42K $25.93K $28.53K
YoY Change 49.46% 75.47% 47.9%
% of Gross Profit 1.73%
Operating Expenses $3.328M $2.755M $3.024M
YoY Change 26.43% -9.09% 26.26%
Operating Profit -$1.400M -$2.761M -$3.060M
YoY Change -47.05% -9.01% 27.72%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $25.85K $1.710K $1.740K
YoY Change 2592.71% -97.95% -2.25%
Pretax Income -$1.374M -$2.760M -$3.058M
YoY Change -48.0% -6.5% 27.74%
Income Tax
% Of Pretax Income
Net Earnings -$1.374M -$2.760M -$3.058M
YoY Change -48.0% -6.5% 27.74%
Net Earnings / Revenue -68.33% -8610.96% -8359.94%
Basic Earnings Per Share -$0.17 -$0.19
Diluted Earnings Per Share -$84.78K -$0.17 -$188.9K
COMMON SHARES
Basic Shares Outstanding 16.21M shares 16.19M shares 16.19M shares
Diluted Shares Outstanding 16.19M shares 16.19M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.14M $10.18M $12.87M
YoY Change 61.44% 13.21% 14.15%
Cash & Equivalents $8.160M $10.18M $12.87M
Short-Term Investments $2.981M
Other Short-Term Assets $296.7K $296.6K $315.1K
YoY Change 21.56% 57.41% 288.87%
Inventory $704.5K $454.3K $221.9K
Prepaid Expenses $296.6K $296.6K
Receivables $33.24K $36.58K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.18M $10.93M $13.44M
YoY Change 66.97% 17.88% 18.38%
LONG-TERM ASSETS
Property, Plant & Equipment $353.6K $315.3K $523.0K
YoY Change 58.33% -20.69% 25.57%
Goodwill
YoY Change
Intangibles $111.9K $117.5K
YoY Change -16.63%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $646.8K $641.7K $646.0K
YoY Change 0.06% 19.43% 14.98%
TOTAL ASSETS
Total Short-Term Assets $12.18M $10.93M $13.44M
Total Long-Term Assets $646.8K $641.7K $646.0K
Total Assets $12.82M $11.57M $14.09M
YoY Change 61.52% 17.96% 18.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $927.7K $325.0K $446.0K
YoY Change 75.42% 9.65% 28.99%
Accrued Expenses $715.8K $487.2K $362.0K
YoY Change 11.11% 11.54% -3.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.099M $814.5K $810.2K
YoY Change 162.22% 9.06% 7.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $119.6K $138.0K $156.0K
YoY Change -41.07% -33.34% -49.12%
Total Long-Term Liabilities $119.6K $138.0K $156.0K
YoY Change -41.07% -33.34% -49.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.099M $814.5K $810.2K
Total Long-Term Liabilities $119.6K $138.0K $156.0K
Total Liabilities $3.218M $952.5K $966.3K
YoY Change 132.43% -0.14% -8.59%
SHAREHOLDERS EQUITY
Retained Earnings -$50.83M -$49.45M
YoY Change 24.49%
Common Stock $16.22K $16.20K
YoY Change 35.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.604M $10.62M $13.12M
YoY Change
Total Liabilities & Shareholders Equity $12.82M $11.57M $14.09M
YoY Change 61.52% 17.96% 18.22%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.374M -$2.760M -$3.058M
YoY Change -48.0% -6.5% 27.74%
Depreciation, Depletion And Amortization $33.42K $25.93K $28.53K
YoY Change 49.46% 75.47% 47.9%
Cash From Operating Activities $1.018M -$2.637M -$3.222M
YoY Change -150.16% 15.17% 35.37%
INVESTING ACTIVITIES
Capital Expenditures -$66.19K -$54.23K -$93.32K
YoY Change 88.52% 81.31% 4430.1%
Acquisitions
YoY Change
Other Investing Activities -$2.970M
YoY Change
Cash From Investing Activities -$3.036M -$54.23K -$93.32K
YoY Change 8546.34% 81.31% 4430.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -320.0
YoY Change -100.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities 1.018M -2.637M -3.222M
Cash From Investing Activities -3.036M -54.23K -93.32K
Cash From Financing Activities 0.000 0.000 -320.0
Net Change In Cash -2.018M -2.691M -3.315M
YoY Change -3.42% 17.84% -179.98%
FREE CASH FLOW
Cash From Operating Activities $1.018M -$2.637M -$3.222M
Capital Expenditures -$66.19K -$54.23K -$93.32K
Free Cash Flow $1.084M -$2.582M -$3.128M
YoY Change -154.36% 14.29% 31.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40439
dei Entity Registrant Name
EntityRegistrantName
NeuroOne Medical Technologies Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0863354
dei Entity Address Address Line1
EntityAddressAddressLine1
7599 Anagram Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Eden Prairie
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55344
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NMTC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16209232 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10178233 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6901346 usd
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
134207 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
208928 usd
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288948 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
315260 usd
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48336 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
454285 usd
CY2021Q3 us-gaap Inventory Net
InventoryNet
98287 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
296571 usd
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
244043 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
10929089 usd
CY2021Q3 us-gaap Assets Current
AssetsCurrent
7292012 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
117471 usd
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
223329 usd
CY2022Q2 us-gaap Assets
Assets
11570748 usd
CY2021Q3 us-gaap Assets
Assets
7938496 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
325027 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
528829 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
487244 usd
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
644249 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
2248 usd
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
8622 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
814519 usd
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1181700 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
137959 usd
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
202895 usd
CY2022Q2 us-gaap Liabilities
Liabilities
952478 usd
CY2021Q3 us-gaap Liabilities
Liabilities
1384595 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16194616 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16194616 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12010019 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12010019 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
16195 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
12010 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60054543 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47369090 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49452468 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40827199 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10618270 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6553901 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11570748 usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7938496 usd
CY2022Q2 us-gaap Revenues
Revenues
32049 usd
CY2021Q2 us-gaap Revenues
Revenues
40096 usd
us-gaap Revenues
Revenues
102381 usd
us-gaap Revenues
Revenues
129810 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
38462 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
61935 usd
us-gaap Cost Of Revenue
CostOfRevenue
158113 usd
us-gaap Cost Of Revenue
CostOfRevenue
210429 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
-6413 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
-21839 usd
us-gaap Gross Profit
GrossProfit
-55732 usd
us-gaap Gross Profit
GrossProfit
-80619 usd
CY2021Q2 nmtc Revenue From Collaboration
RevenueFromCollaboration
17451 usd
nmtc Revenue From Collaboration
RevenueFromCollaboration
6374 usd
nmtc Revenue From Collaboration
RevenueFromCollaboration
59838 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1529670 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2129474 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5090018 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4636586 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1225351 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
901134 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3491193 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2916721 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2755021 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
3030608 usd
us-gaap Operating Expenses
OperatingExpenses
8581211 usd
us-gaap Operating Expenses
OperatingExpenses
7553307 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2761434 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3034996 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8630569 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7574088 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3053 usd
nmtc Net Valuation Change Of Instruments Measured At Fair Value
NetValuationChangeOfInstrumentsMeasuredAtFairValue
1974 usd
CY2022Q2 us-gaap Other Income
OtherIncome
1707 usd
CY2021Q2 us-gaap Other Income
OtherIncome
83387 usd
us-gaap Other Income
OtherIncome
5300 usd
us-gaap Other Income
OtherIncome
270162 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2759727 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2951609 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8625269 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7305005 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2759727 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2951609 usd
us-gaap Net Income Loss
NetIncomeLoss
-8625269 usd
us-gaap Net Income Loss
NetIncomeLoss
-7305005 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16193442 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11959101 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15927734 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10269216 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2066172 usd
CY2020Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1005232 usd
CY2020Q4 nmtc Issuance Cost Settlement In Connection With Private Placement
IssuanceCostSettlementInConnectionWithPrivatePlacement
50400 usd
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
245829 usd
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-1959480 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1408153 usd
CY2021Q1 nmtc Issuance Costs In Connection With Private Placement
IssuanceCostsInConnectionWithPrivatePlacement
8829236 usd
CY2021Q1 nmtc Issuance Of Warrants Stock In Connection With Private Placement
IssuanceOfWarrantsStockInConnectionWithPrivatePlacement
3670764 usd
CY2021Q1 nmtc Issuance Cost Settlement In Connection With Private Placement
IssuanceCostSettlementInConnectionWithPrivatePlacement
-1198080 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
326359 usd
CY2021Q1 nmtc Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
212499 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4998 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2393916 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10860013 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
878852 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5148 usd
CY2021Q2 nmtc Stock Issue During Period Value Exercise Of Stock Warrants
StockIssueDuringPeriodValueExerciseOfStockWarrants
62501 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2951609 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
8854905 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6553901 usd
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13350582 usd
CY2021Q4 nmtc Issuance Cost In Connection With Public Offering
IssuanceCostInConnectionWithPublicOffering
-1352280 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
203072 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-2807475 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15947800 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
232716 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3058067 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13122449 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
255548 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2759727 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10618270 usd
us-gaap Net Income Loss
NetIncomeLoss
-8625269 usd
us-gaap Net Income Loss
NetIncomeLoss
-7305005 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85198 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58385 usd
nmtc Allocated Share Based Compensation
AllocatedShareBasedCompensation
691336 usd
nmtc Allocated Share Based Compensation
AllocatedShareBasedCompensation
1451040 usd
nmtc Issuance Costs Attributed To Financing Activities
IssuanceCostsAttributedToFinancingActivities
3053 usd
nmtc Revaluation Of Convertible Notes
RevaluationOfConvertibleNotes
-1974 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-80020 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-41056 usd
nmtc Payroll Protection Program Loan Forgiveness
PayrollProtectionProgramLoanForgiveness
83333 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-48336 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
40096 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
355998 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
52182 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
145462 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
45620 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87197 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-466128 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-228315 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-132716 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8537351 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6573520 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
209044 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31970 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209044 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31970 usd
nmtc Issuance Costs In Connection With Convertible Promissory Notes
IssuanceCostsInConnectionWithConvertiblePromissoryNotes
3053 usd
nmtc Proceeds From Issuance Of Common Stock In Connection With Public Offering And Private Placements
ProceedsFromIssuanceOfCommonStockInConnectionWithPublicOfferingAndPrivatePlacements
13350582 usd
nmtc Proceeds From Issuance Of Common Stock In Connection With Public Offering And Private Placements
ProceedsFromIssuanceOfCommonStockInConnectionWithPublicOfferingAndPrivatePlacements
8829236 usd
nmtc Proceeds From Issuance Of Warrant In Connection With Private Placement
ProceedsFromIssuanceOfWarrantInConnectionWithPrivatePlacement
3670764 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
275000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10146 usd
nmtc Deferreds Offering Costs
DeferredsOfferingCosts
24179 usd
nmtc Issuance Costs Related To Public Offering And Private Placements
IssuanceCostsRelatedToPublicOfferingAndPrivatePlacements
1327300 usd
nmtc Issuance Costs Related To Public Offering And Private Placements
IssuanceCostsRelatedToPublicOfferingAndPrivatePlacements
1198080 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12023282 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11559834 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3276887 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4954344 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6901346 usd
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4036397 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10178233 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8990741 usd
nmtc Conversion Of Convertible Promissory Notes To Equity
ConversionOfConvertiblePromissoryNotesToEquity
1005232 usd
nmtc Unpaid Issuance Costs Attributed To Convertible Notes And Private Placement
UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement
50400 usd
nmtc Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering
ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering
24980 usd
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Royalty Expense
RoyaltyExpense
25000 usd
CY2022Q2 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
49500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management’s Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes when outstanding, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1007206 usd
nmtc Change In Fair Value Including Accrued Interest
ChangeInFairValueIncludingAccruedInterest
-1974 usd
nmtc Conversion Of Convertible Promissory Notes To Common Stock
ConversionOfConvertiblePromissoryNotesToCommonStock
-1005232 usd
nmtc Warrantshares
Warrantshares
6753444 shares
nmtc Warrantshares
Warrantshares
7503808 shares
nmtc Number Of Licencing Agreements
NumberOfLicencingAgreements
2 pure
nmtc Stock Options
StockOptions
1245582 shares
nmtc Stock Options
StockOptions
1162838 shares
nmtc Restricted Stock Unit
RestrictedStockUnit
443670 shares
nmtc Restricted Stock Unit
RestrictedStockUnit
18176 shares
CY2020Q2 nmtc Royalty Minimum Payments Year One
RoyaltyMinimumPaymentsYearOne
50000 usd
CY2021Q2 nmtc Royalty Minimum Payments Year Two
RoyaltyMinimumPaymentsYearTwo
100000 usd
CY2022Q2 nmtc Royalty Minimum Payments Year Three
RoyaltyMinimumPaymentsYearThree
150000 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
37500 usd
us-gaap Royalty Expense
RoyaltyExpense
100000 usd
CY2020Q4 us-gaap Litigation Settlement Amount Awarded From Other Party
LitigationSettlementAmountAwardedFromOtherParty
185000 usd
nmtc Lease Agreement Description
LeaseAgreementDescription
On October 7, 2019, the Company entered into a non-cancellable lease agreement (the “Minnesota Lease”) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the “Landlord”) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Minnesota Lease ending 65 months after such date, unless terminated earlier (the “Term”). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Minnesota Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. The Company will also pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Minnesota Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months. 
CY2021Q3 nmtc Lease Space
LeaseSpace
1162 sqft
CY2021Q3 nmtc Lease Rental Expense
LeaseRentalExpense
4241 usd
CY2020Q4 nmtc Monthly Lease Rent
MonthlyLeaseRent
504 usd
CY2022Q2 nmtc Rent Expense
RentExpense
42185 usd
nmtc Rent Expense
RentExpense
128315 usd
CY2021Q2 nmtc Rent Expense
RentExpense
31485 usd
nmtc Rent Expense
RentExpense
92746 usd
nmtc Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
97799 usd
nmtc Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
58173 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
208928 usd
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288948 usd
CY2022Q2 nmtc Lease Liability
LeaseLiability
232011 usd
CY2021Q3 nmtc Lease Liability
LeaseLiability
315673 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068 pure
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.067 pure
CY2022Q2 nmtc Lessee Operating Lease Liability Payments Due One Year
LesseeOperatingLeaseLiabilityPaymentsDueOneYear
65856 usd
CY2022Q2 nmtc Lessee Operating Lease Liability Payments Due Two Year
LesseeOperatingLeaseLiabilityPaymentsDueTwoYear
82333 usd
CY2022Q2 nmtc Lessee Operating Lease Liability Payments Due Three Year
LesseeOperatingLeaseLiabilityPaymentsDueThreeYear
84391 usd
CY2022Q2 nmtc Lessee Operating Lease Liability Payments Due Four Year
LesseeOperatingLeaseLiabilityPaymentsDueFourYear
21227 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
253807 usd
CY2022Q2 nmtc Imputed Interest
ImputedInterest
-21796 usd
CY2022Q2 nmtc Lease Liability Net
LeaseLiabilityNet
232011 usd
CY2022Q2 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
94052 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
137959 usd
CY2022Q2 nmtc Prepaid Expenses
PrepaidExpenses
296572 usd
CY2021Q3 nmtc Prepaid Expenses
PrepaidExpenses
151109 usd
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
92934 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
296572 usd
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
244043 usd
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
134207 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16736 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
117471 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
5578 usd
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
16736 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
5579 usd
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
16737 usd
CY2022Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
471879 usd
CY2021Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
311486 usd
CY2022Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1895 usd
CY2021Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1895 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
473774 usd
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
313381 usd
CY2022Q2 nmtc Less Accumulated Depreciations
LessAccumulatedDepreciations
-158514 usd
CY2021Q3 nmtc Less Accumulated Depreciations
LessAccumulatedDepreciations
-90052 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
315260 usd
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
223329 usd
CY2022Q2 us-gaap Depreciation
Depreciation
25928 usd
us-gaap Depreciation
Depreciation
68462 usd
CY2021Q2 us-gaap Depreciation
Depreciation
14776 usd
us-gaap Depreciation
Depreciation
41648 usd
CY2022Q2 nmtc Accrued Payroll
AccruedPayroll
287962 usd
CY2021Q3 nmtc Accrued Payroll
AccruedPayroll
376236 usd
CY2022Q2 nmtc Lease Liability Shortterms
LeaseLiabilityShortterms
94052 usd
CY2021Q3 nmtc Lease Liability Shortterms
LeaseLiabilityShortterms
112778 usd
CY2022Q2 nmtc Royalty Payments
RoyaltyPayments
75230 usd
CY2021Q3 nmtc Royalty Payments
RoyaltyPayments
72083 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000 usd
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
83152 usd
CY2022Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
487244 usd
CY2021Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
644249 usd
nmtc Intial Fee Payment
IntialFeePayment
2000000 usd
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
8622 usd
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
73434 usd
nmtc Revenue Recognized
RevenueRecognized
6374 usd
nmtc Revenue Recognized
RevenueRecognized
59838 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
2248 usd
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
13596 usd
CY2022Q2 us-gaap Advertising Expense
AdvertisingExpense
43479 usd
us-gaap Advertising Expense
AdvertisingExpense
218011 usd
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
79261 usd
us-gaap Advertising Expense
AdvertisingExpense
221408 usd
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
3234800 usd
CY2020Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.13 pure
CY2020Q4 us-gaap Investment Maturity Date
InvestmentMaturityDate
2020-11-01
nmtc Interest On Principal Amount
InterestOnPrincipalAmount
5701 usd
nmtc Changes Of Fair Value Benefit
ChangesOfFairValueBenefit
-1974 usd
nmtc Warrants Description
WarrantsDescription
Each 2019 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.
CY2019Q4 nmtc Warrants To Purchase Of Common Stock Shares
WarrantsToPurchaseOfCommonStockShares
288305 shares
nmtc Expire Date
ExpireDate
November 1, 2022
us-gaap Legal Fees
LegalFees
3053 usd
CY2020Q4 us-gaap Accrued Utilities Current And Noncurrent
AccruedUtilitiesCurrentAndNoncurrent
615159 usd
CY2020Q4 nmtc Converted Notes Common Stock
ConvertedNotesCommonStock
292754 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
88690 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
81446 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
150690 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
703117 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.57
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.01
nmtc Expense Related To Restricted Stock Units
ExpenseRelatedToRestrictedStockUnits
444891 usd
nmtc Expense Related To Restricted Stock Units
ExpenseRelatedToRestrictedStockUnits
817761 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1245582 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1122560 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.535 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.56 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.535 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.559 pure
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
265901 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
268793 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27668 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31583 shares
CY2021Q2 nmtc Shares Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1693 usd
nmtc Shares Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2648 usd
CY2021Q2 us-gaap Restricted Stock Expense
RestrictedStockExpense
13776 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
13776 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
7.26
CY2021Q2 nmtc Consulting Agreements Description
ConsultingAgreementsDescription
two consulting agreements were executed whereby a total of 62,659 shares of common stock were subject to issuance of which 51,330 shares of common stock were issued as of June 30, 2021. Compensation expense related to the stock awards granted under these consulting agreements amounted to $339,001 for the three and nine months ended June 30, 2021 and were included in the total stock-based compensation expense.
CY2021Q4 nmtc Shares Of Common Stock
SharesOfCommonStock
420350 shares
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1927956 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
nmtc Gross Proceed
GrossProceed
13400000 usd
nmtc Other Offering Expenses Payable
OtherOfferingExpensesPayable
1400000 usd
CY2021Q3 nmtc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber
7503808 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M23D
CY2022Q2 nmtc Warrants Forfeited Expiredin Shares1
WarrantsForfeitedExpiredinShares1
-750364 shares
CY2022Q2 nmtc Exercise Price Per Warrant Forfeited Expired1
ExercisePricePerWarrantForfeitedExpired1
5.4
CY2022Q2 nmtc Weighted Average Exercise Price Forfeited Expired
WeightedAverageExercisePriceForfeitedExpired
5.4
CY2022Q2 nmtc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber
6753444 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P2Y9M25D
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1 pure
nmtc Contributions Percentage
ContributionsPercentage
0.03 pure
nmtc Internal Revenue Percentage
InternalRevenuePercentage
1 pure
CY2022Q2 nmtc Contributions Amount
ContributionsAmount
30697 usd
nmtc Contributions Amount
ContributionsAmount
14803 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
350000 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.0499 pure
us-gaap Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger
DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
0.1999 pure
dei City Area Code
CityAreaCode
952
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2022Q2 nmtc Net Valuation Change Of Instruments Measured At Fair Value
NetValuationChangeOfInstrumentsMeasuredAtFairValue
usd
CY2021Q2 nmtc Net Valuation Change Of Instruments Measured At Fair Value
NetValuationChangeOfInstrumentsMeasuredAtFairValue
usd
nmtc Net Valuation Change Of Instruments Measured At Fair Value
NetValuationChangeOfInstrumentsMeasuredAtFairValue
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10269216 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11959101 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15927734 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16193442 shares
CY2020Q4 nmtc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
usd
CY2021Q1 nmtc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
usd
CY2021Q2 nmtc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
usd
CY2021Q4 nmtc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
usd
nmtc Issuance Costs Attributed To Financing Activities
IssuanceCostsAttributedToFinancingActivities
usd
nmtc Revaluation Of Convertible Notes
RevaluationOfConvertibleNotes
usd
nmtc Issuance Costs In Connection With Convertible Promissory Notes
IssuanceCostsInConnectionWithConvertiblePromissoryNotes
usd
nmtc Proceeds From Issuance Of Warrant In Connection With Private Placement
ProceedsFromIssuanceOfWarrantInConnectionWithPrivatePlacement
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
nmtc Deferreds Offering Costs
DeferredsOfferingCosts
usd
nmtc Conversion Of Convertible Promissory Notes To Equity
ConversionOfConvertiblePromissoryNotesToEquity
usd
nmtc Unpaid Issuance Costs Attributed To Convertible Notes And Private Placement
UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement
usd
nmtc Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering
ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering
usd
CY2021Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
usd
nmtc Operating Leases
OperatingLeases
usd
nmtc Operating Leases
OperatingLeases
usd
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2022Q2 nmtc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Periods
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriods
shares
CY2022Q2 nmtc Exercise Price Per Warrant Issued1
ExercisePricePerWarrantIssued1
CY2022Q2 nmtc Weighted Average Exercise Price Issued
WeightedAverageExercisePriceIssued
nmtc Weighted Average Termyears Issuedin Shares
WeightedAverageTermyearsIssuedinShares
CY2022Q2 nmtc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Periods
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriods
shares
CY2022Q2 nmtc Weighted Average Exercise Price Exercised1
WeightedAverageExercisePriceExercised1
CY2022Q2 nmtc Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Pricee1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricee1
nmtc Weighted Average Termyears Exercisedin Shares
WeightedAverageTermyearsExercisedinShares
nmtc Weighted Average Termyears Forfeitedin Shares
WeightedAverageTermyearsForfeitedinShares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001500198

Files In Submission

Name View Source Status
0001213900-22-046902-index-headers.html Edgar Link pending
0001213900-22-046902-index.html Edgar Link pending
0001213900-22-046902.txt Edgar Link pending
0001213900-22-046902-xbrl.zip Edgar Link pending
f10q0622ex10-1_neuroone.htm Edgar Link pending
f10q0622ex10-2_neuroone.htm Edgar Link pending
f10q0622ex31-1_neuroone.htm Edgar Link pending
f10q0622ex31-2_neuroone.htm Edgar Link pending
f10q0622ex32-1_neuroone.htm Edgar Link pending
f10q0622ex32-2_neuroone.htm Edgar Link pending
f10q0622ex4-1_neuroone.htm Edgar Link pending
f10q0622_neuroonemedical.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtc-20220630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
nmtc-20220630_cal.xml Edgar Link unprocessable
nmtc-20220630_lab.xml Edgar Link unprocessable
nmtc-20220630_def.xml Edgar Link unprocessable
nmtc-20220630_pre.xml Edgar Link unprocessable
f10q0622_neuroonemedical_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable